Therefore, STAT3 inhibitors have great potential as novel targeted agents in NHL [35], and early-stage studies of STAT3 inhibitors have shown encouraging results in NHL treatment [36, 37]. The gene discussed is STAT3; the disease is non-Hodgkin lymphoma.